Optimal treatment strategy for a patient with advanced ovarian cancer without deterioration in the quality of life: a clinical case
- Authors: Khokhlova S.V1
-
Affiliations:
- National Medical Research Center for Obstetrics, Gynecology and Perinatology n.a. Acad. V.I. Kulakov
- Issue: Vol 26, No 12 (2019)
- Pages: 112-120
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312363
- DOI: https://doi.org/10.18565/pharmateca.2019.12.112-119
- ID: 312363
Cite item
Open Access
Access granted
Abstract
Background. Platinum-containing combinations of drugs remain the drug of choice both for the 1st-line therapy and the therapy of platinum-sensitive relapses for patients with ovarian cancer. In some cases, it is necessary to select alternative approaches to reduce the effects of toxicity, allergic reactions, as well as in the case of relapses that develop in the interval without treatment for less than 1 year. Description of the clinical case. A patient with a diagnosis of T3CN0M0, grade III, was admitted with complaints of ascites, an increase in the volume of the abdomen, weakness, shortness of breath during physical exertion. An additional examination revealed cystic and solid components in both ovaries, metastases along the peritoneum, forming confluent dissemination along the peritoneum of the pelvis, with extension to the greater omentum. Due to the stage of the disease and the moderately grave condition of the patient, it was decided to start with neoadjuvant chemotherapy (CT) according to the scheme: paclitaxel + carboplatin with a partial effect according to ultrasound examination and a decrease in the CA marker level. Extirpation of the uterus with appendages, removal of a large omentum in a non-optimal volume was performed. Due to the treatment, it was possible to increase the time to the third chemotherapy by 20 months, which allowed the patient to recover after the previous taxane-platinum therapy. A further strategy for choosing CT taking into account factors such as residual polyneuropathy stage 1, the presence of a BRCA1 mutation, the patient’s desire to use drugs that do not cause alopecia, is described. Subsequently, the patient received olaparib in a maintenance regimen for 16 months; good tolerability of treatment was noted. Conclusion. The case described indicates the importance of competent sequential alternation of treatment of patients with ovarian cancer, which allows achieving significant stabilization of the patients’ condition, regression of the oncological process, without deterioration in the quality of their life.
Full Text
About the authors
S. V Khokhlova
National Medical Research Center for Obstetrics, Gynecology and Perinatology n.a. Acad. V.I. Kulakov
Email: svkhokhlova@mail.ru
4, Academician Oparin Street, Moscow 117198, Russian Federation
References
- Monk B.J., Dalton H, Benjamin I. et al. Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer. Curr Pharm Des. 2012;18(25):3754-69.
- Colombo N. Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient. EJCSuppl. 2014;12(2):7-12. doi: 10.1016/S1359-6349(15)70004-2.
- Colmegna B, Uboldi S, Frapolli R., et al. Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin. Br J Cancer. 2015;113(12):1687-93. Doi: 10.1038/ bjc.2015.407.
- Colmegna B, Uboldi S, Erba E., et al. Resistance to minor groove binders. Drug Discov Today Technol. 2014;11:73-9. Doi: 10.1016/j. ddtec.2014.03.001.
- Monk B.J., Sill M.W,. Hanjani F.I., et al. Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2011;120(3):459-63. Doi: 10.1016/j. ygyno.2010.11.012.
- Monk B.J., Kaye S.B., Poveda A., et al. Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial. Gynecol Oncol. 2014;132(1):176-80. doi: 10.1016/j.ygyno.2013.10.032.
- Poveda A, Ray-Coquard I., Romero I., et al. Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin. Cancer Treat Rev. 2014;40(3):366-75. doi: 10.1016/j.ctrv.2013.08.001.
- Windebank A.J., Grisold W. Chemotherapy-induced neuropathy. J Peripher NervSyst. 2008;13(1):27-46. doi: 10.1111/j.1529-8027.2008.00156.x.
- Pignata S, Ferrandina G, Scarfone G., et al. Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. BMC Cancer. 2008;8:252. doi: 10.1186/1471- 2407-8-252.
- Dunton C.J. Management of treatment-related toxicity in advanced ovarian cancer. Oncologist. 2002;7 Suppl 5:11-9.
- Gonzalez-Martfn A., Toledo G., Chiva L. Epithelial ovarian carcinoma: current evidences and future perspectives in the first-line setting. Clin Transl Oncol. 2010;12(6):418-30. Doi: 10.1007/ s12094-010-0529-1.
- Daniels M.S., Babb S.A., King R.H., et al. Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study. J Clin Oncol. 2014;32(12):1249-55. doi: 10.1200/JCO.2013.50.6055.
- Murai J., Huang S.Y, Das B.B., et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012;72(21):5588-99. doi: 10.1158/0008-5472.CAN-12-2753.
- Farmer H., McCabe N., Lord C.J. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917-21.
- Ledermann J., Harter P, Gourley C., et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382-92. Doi: 10.1056/ NEJMoa1105535.
- Matulonis U.A., Harter P, Gourley C., et al. Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer. 2016;122(12):1844-52. Doi: 10.1002/ cncr. 29995.
- Sanchez R.I., Wang R.W., Newton D.J., et al. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos. 2004;32(11):1287-92. Doi: 10.1124/ dmd.104.000216.
- Thigpen T., duBois A., McAlpine J., et al. Firstline therapy in ovarian cancer trials. Int J Gynecol Cancer. 2011;21(4):756-62 Doi: 10.1097/ IGC.0b013e31821ce75d.
- Ledermann J.A., Raja F.A., Fotopoulou C., et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;6:vi24-32. doi: 10.1093/annonc/mdt333
Supplementary files
